PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study

Objective: Dual PEGylated interferon-(PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and management complexity of treatment. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	Javier Milara, Maria Outeda-Macias, Mª Dolores Aumente-rubio, Patricio Más-Serrano, Azucena Aldaz, Mª Victoria Calvo, Mª Sergia García-Simón, Marisa Martin-Barbero, Núria Padullés-Zamora, Juan Antonio Schoenenberger, Marianne Saavedra-Aldrich, Enrique Tévar-Alfonso, Ana Saval, Alfonso Pastor-Clerigues, Marta García, Luis Margusino-Framiñan, Jose Luis Montero-Alvarez, Esperanza Merino, Jose Ignacio Herrero, Mónica Beunza, Pablo Conesa-Zamora, Alvaro Gimenez-Manzorro, Dolors Comas-Sugrañes, Manuel Cano-Marron, Elena Jiménez-Mutiloa, Pilar Díaz-Ruíz, Julio Cortijo
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Farmacia Hospitalaria
Subjects:	Hepatitis C ; Pharmacogenetics Sustained viral response ; TNFRSF1B
Online Access:	http://www.aulamedica.es/fh/pdf/8547.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study

Similar Items